Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling.

Publication ,  Journal Article
Namey, E; Agot, K; Ahmed, K; Odhiambo, J; Skhosana, J; Guest, G; Corneli, A
Published in: Cult Health Sex
September 2016

Oral pre-exposure prophylaxis (PrEP) using the antiretroviral drug emtricitabine/tenofovir disoproxil fumarate (Truvada) has been shown to dramatically reduce the risk of HIV acquisition for women at higher risk of infection if taken daily. Understanding when and why women would intentionally stop using an efficacious oral PrEP drug within the context of their 'normal' daily lives is essential for delivering effective PrEP risk-reduction counselling. As part of a larger study, we conducted 60 qualitative interviews with women at higher risk of HIV in Bondo, Kenya, and Pretoria, South Africa. Participants charted their sexual contacts over the previous six months, indicated whether they would have taken PrEP if available and discussed whether and why they would have suspended PrEP use. Nearly all participants said they would have used PrEP in the previous six months; half indicated they would have suspended PrEP use at some point. Participants' reasons for an extended break from PrEP were related to partnership dynamics (e.g., perceived low risk of a stable partner) and phases of life (e.g., trying to conceive). Life events (e.g., holidays and travel) could prompt shorter breaks in PrEP use. These circumstances may or may not correspond to actual contexts of lower risk, highlighting the importance of tailored PrEP risk-reduction counselling.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cult Health Sex

DOI

EISSN

1464-5351

Publication Date

September 2016

Volume

18

Issue

9

Start / End Page

1081 / 1091

Location

England

Related Subject Headings

  • Travel
  • South Africa
  • Sexual Partners
  • Sexual Behavior
  • Safe Sex
  • Risk Reduction Behavior
  • Qualitative Research
  • Public Health
  • Pre-Exposure Prophylaxis
  • Medication Adherence
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Namey, E., Agot, K., Ahmed, K., Odhiambo, J., Skhosana, J., Guest, G., & Corneli, A. (2016). When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. Cult Health Sex, 18(9), 1081–1091. https://doi.org/10.1080/13691058.2016.1164899
Namey, Emily, Kawango Agot, Khatija Ahmed, Jacob Odhiambo, Joseph Skhosana, Greg Guest, and Amy Corneli. “When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling.Cult Health Sex 18, no. 9 (September 2016): 1081–91. https://doi.org/10.1080/13691058.2016.1164899.
Namey E, Agot K, Ahmed K, Odhiambo J, Skhosana J, Guest G, et al. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. Cult Health Sex. 2016 Sep;18(9):1081–91.
Namey, Emily, et al. “When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling.Cult Health Sex, vol. 18, no. 9, Sept. 2016, pp. 1081–91. Pubmed, doi:10.1080/13691058.2016.1164899.
Namey E, Agot K, Ahmed K, Odhiambo J, Skhosana J, Guest G, Corneli A. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. Cult Health Sex. 2016 Sep;18(9):1081–1091.

Published In

Cult Health Sex

DOI

EISSN

1464-5351

Publication Date

September 2016

Volume

18

Issue

9

Start / End Page

1081 / 1091

Location

England

Related Subject Headings

  • Travel
  • South Africa
  • Sexual Partners
  • Sexual Behavior
  • Safe Sex
  • Risk Reduction Behavior
  • Qualitative Research
  • Public Health
  • Pre-Exposure Prophylaxis
  • Medication Adherence